Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...
Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...
Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
More than 90 per cent of weight loss jab users are forced to pay for treatment privately due to their slow roll-out on the ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...